Arrowhead Pharmaceuticals to Present Important Clinical Data at the American Heart Association Scientific Sessions 2026
Key Highlights
- ➤ARO-DIMER-PA Phase 1/2a data to be presented at AHA 2026
- ➤Pooled SHASTA-3/4 analysis to assess triglyceride lowering and pancreatitis risk
- ➤Plozasiran three-year PALISADE and open-label extension data to be presented
- ➤Plozasiran received FDA STAR pilot entry for upcoming sHTG sNDA
- ➤REDEMPLO approved across multiple jurisdictions for familial chylomicronemia syndrome
Expert Statements
Luke Laffin, M.D.; Co-Director, Center for Blood Pressure Disorders, and Medical Director of Cardiac Rehabilitation at the Cleveland Clinic
“First-in-Human Trial of a Dual Functional RNAi Molecule to Silence Expression of Both PCSK9 and APOC3 in Mixed Hyperlipidemia (ARO-DIMER-PA)”
Christie Ballantyne, M.D.; Chief of Cardiology and Cardiovascular Research, Baylor College of Medicine, and Director, Center for Cardiometabolic Disease Prevention at the Houston Methodist DeBakey Heart and Vascular Center
“Triglyceride Lowering and Acute Pancreatitis (AP) Risk Reduction with Plozasiran in Severe Hypertriglyceridemia (sHTG): A Pooled Analysis of SHASTA-3 and SHASTA-4”
Robert Rosenson, M.D.; Dr. Rony Shimony Distinguished Professor of Cardiovascular Medicine at the Icahn School of Medicine at Mount Sinai and System Director of Metabolism and Lipids for the Mount Sinai Health System
“Long Term Efficacy and Safety of Plozasiran in Patients with Familial Chylomicronemia Syndrome: 3-Year Data from the PALISADE Study and the Open-Label Extension”
Daniel Gaudet, M.D., Ph.D.; Department of Medicine, Université de Montréal and ECOGENE 21 Clinical Research Center
“Impact of GLP-1 Receptor Agonist Use on Triglyceride Reduction with Plozasiran”
Arrowhead Pharmaceuticals to Present Important Clinical Data at the American Heart Association Scientific Sessions 2026
– Detailed Results from the Phase 1/2a Study of ARO-DIMER-PA, the First Dual-Functional Investigational RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia, Will Be Presented at Late-breaking Featured Science Session.05 on Saturday, November 7 –
Get started
Create a free account to read the full story.